Insmed Incorporated Q4 2025 Earnings Call Summary

Core Insights - The exceptional performance in 2025 is attributed to the early launch of Brinsupri and accelerated growth of ARIKAYCE, particularly in Japan and Europe [1] Group 1: Product Performance - Brinsupri achieved $144.6 million in net revenue during its first full quarter, positioning it as potentially the best specialty respiratory launch in history [1] - ARIKAYCE experienced 40% year-over-year growth in Japan, contributing over a quarter of the product's global revenue [1] Group 2: Market Strategy - The company aims to dominate the bronchiectasis and NTM categories by leveraging a similar call point among pulmonologists for both lead therapies [1] - The current peak sales estimate for Brinsupri is $5 billion, which only accounts for 250,000 patients with frequent exacerbations, indicating significant potential in the broader diagnosed population [1] Group 3: Future Outlook - The company is entering an 'exploration stage' where positive patient feedback is expected to enhance prescribing depth as physicians expand beyond initial trial patients [1]